# Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001

> **NCT03574818** · PHASE2 · TERMINATED · sponsor: **Montefiore Medical Center** · enrollment: 1 (actual)

## Conditions studied

- Squamous Cell Lung Cancer

## Interventions

- **DRUG:** Necitumumab-Gemcitabine-Cisplatin
- **DIAGNOSTIC_TEST:** Evaluation to determine if patient is a candidate to proceeed with surgical resection or not

## Key facts

- **NCT ID:** NCT03574818
- **Lead sponsor:** Montefiore Medical Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-05-29
- **Primary completion:** 2018-10-25
- **Final completion:** 2019-09-26
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2020-03-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03574818

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03574818, "Necitumumab in the Neoadjuvant Setting With Gemcitabine in Surgically Resectable - 14X-US-I001". Retrieved via AI Analytics 2026-06-30 from https://api.ai-analytics.org/clinical/NCT03574818. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*